View Item 

Show simple item record

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
dc.contributor.authorFleischmann, Roy
dc.contributor.authorWeinblatt, Michael E.
dc.contributor.authorSchiff, Michael
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorMaldonado, Michael A.
dc.contributor.authorNadkarni, Anagha
dc.contributor.authorFurst, Daniel E.
dc.date.accessioned2016-07-06T18:21:22Z
dc.date.available2017-09-06T14:20:20Zen
dc.date.issued2016-07
dc.identifier.citationFleischmann, Roy; Weinblatt, Michael E.; Schiff, Michael; Khanna, Dinesh; Maldonado, Michael A.; Nadkarni, Anagha; Furst, Daniel E. (2016). "Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis." Arthritis Care & Research 68(7): 907-913.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/122413
dc.publisherWiley Periodicals, Inc.
dc.titlePatient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/122413/1/acr22763_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/122413/2/acr22763.pdf
dc.identifier.doi10.1002/acr.22763
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceGenovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011; 63: 2854 – 64.
dc.identifier.citedreferenceArnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315 – 24.
dc.identifier.citedreferenceDworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105 – 21.
dc.identifier.citedreferenceWells G, Li T, Maxwell L, Maclean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 280 – 9.
dc.identifier.citedreferenceReilly MC, Brown MC, Brahant Y, Gerlier L, Tan SC, Sandborn WJ. Defining the minimally important difference for WPAI. CD scores: what is a relevant impact on work productivity in active Crohn's disease. Gut 2007; 56 Suppl 3: 159.
dc.identifier.citedreferenceWells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 260 – 5.
dc.identifier.citedreferenceStrand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible: response criteria and the importance of change at OMERACT 10. J Rheumatol 2011; 38: 1720 – 7.
dc.identifier.citedreferencePollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005; 23: S43 – 52.
dc.identifier.citedreferenceKirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol 2005; 32: 2250 – 6.
dc.identifier.citedreferenceRupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health‐related quality of life in rheumatoid arthritis. Arthritis Rheum 2004; 51: 578 – 85.
dc.identifier.citedreferenceSchiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi‐centre, randomised, double‐blind, placebo‐controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096 – 103.
dc.identifier.citedreferenceKremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud‐Mendoza C, et al. Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953 – 63.
dc.identifier.citedreferenceWeinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753 – 9.
dc.identifier.citedreferenceKeystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10‐year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40: 1487 – 97.
dc.identifier.citedreferenceStrand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health‐related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012; 39: 63 – 72.
dc.identifier.citedreferenceSmolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631 – 7.
dc.identifier.citedreferenceChaparro del Moral R, Rillo OL, Casalla L, Moron CB, Citera G, Cocco JA, et al. Work productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis 2012; 2012: 137635.
dc.identifier.citedreferenceZhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire: general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12: R177.
dc.identifier.citedreferenceHazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010; 49: 1900 – 10.
dc.identifier.citedreferenceRadner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient‐reported outcomes and costs. Arthritis Res Ther 2014; 16: R56.
dc.identifier.citedreferenceWells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. Biologics 2014; 8: 41 – 55.
dc.identifier.citedreferenceSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625 – 39.
dc.identifier.citedreferenceSmolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux‐Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964 – 75.
dc.identifier.citedreferenceWesthovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate‐naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870 – 7.
dc.identifier.citedreferenceKremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud‐Mendoza C, et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865 – 76.
dc.identifier.citedreferenceKremer JM, Russell AS, Emery P, Abud‐Mendoza C, Szechinski J, Westhovens R, et al. Long‐term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3‐year results from the AIM trial. Ann Rheum Dis 2011; 70: 1826 – 30.
dc.identifier.citedreferenceSmolen J, Dougados M, Gaillez C, Poncet C, Le Bars M, Mody M, et al. Remission according to different composite disease activity indices in biologic‐naive patients with rheumatoid arthritis treated with abatacept or infliximab plus methotrexate. Arthritis Rheum 2011; 63 Suppl: S477.
dc.identifier.citedreferenceWeinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: a one‐year randomized, placebo‐controlled study. Arthritis Rheum 2006; 54: 2807 – 16.
dc.identifier.citedreferenceWesthovens R, Kremer JM, Emery P, Russell AS, Li T, Aranda R, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic‐naïve patients with RA. Ann Rheum Dis 2009; 68 Suppl 3: 577.
dc.identifier.citedreferenceGenovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114 – 23.
dc.identifier.citedreferenceSchiff M, Pritchard C, Huffstutter JE, Rodriguez‐Valverde V, Durez P, Zhou X, et al. The 6‐month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti‐tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68: 1708 – 14.
dc.identifier.citedreferenceWeinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013; 65: 28 – 38.
dc.identifier.citedreferenceSchiff M, Weinblatt M, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab on background methotrexate in RA: two year results from the AMPLE study. Ann Rheum Dis 2013; 72 Suppl 3: 64.
dc.identifier.citedreferenceSchiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two‐year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73: 86 – 94.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22763_am.pdf
Size:
820.1KB
Format:
PDF
View/Open
Name:
acr22763.pdf
Size:
518.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.